secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tarsus Pharmaceuticals, Inc. (TARS)
CIK:        0001819790
Form:       8-K
Filed at:   2026-07-08T20:13:40+00:00
Accession:  0001819790-26-000046
Event type: m_and_a
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 3.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tarsus acquires iRenix Medical for ~$75M upfront; adds late-stage ocular antiseptic IRX-101
--------------------------------------------------------------------------------

- Upfront consideration of $75M: $37.5M cash + $37.5M in Tarsus common stock (607,093 shares).
- Potential approval/commercial milestones up to $490M plus low-to-mid single-digit revenue sharing.
- IRX-101 Phase 2b/3 RELIEF trial: ~50% relative reduction in post-procedural pain (p=0.0003) vs povidone-iodine.
- Phase 3 study expected to start H1 2027 with results in 2028; FDA-aligned program.
- Over 11M intravitreal injections performed annually in US; no new FDA-approved ocular antiseptic in >40 years.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1819790/000181979026000046/0001819790-26-000046-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1819790/000181979026000046/tars-20260706.htm
  HTML page:      https://secwatch.observer/filing/0001819790-26-000046

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer